- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 4, 2022
Deals
Amgen sees Tavneos as growth opportunity with $4B ChemoCentryx buyout
With patent expirations ahead, deal gives Amgen immunology asset approved for vasculitis indication, with potential for label expansions
Items per page:
1 - 6 of 6